Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

<< Back to News

03/16/20 dc albuterol MDIs
March 17, 2020

From: "David Collette" <david.collette@hhsys.org>
To: "grp allpharm" <grp_allpharm@hhsys.org>
Cc: "Keith Moss" <keith.moss@hhsys.org>, "Robert W Jr Chappell" <robert.chappell@hhsys.org>, "Doughty Tracy" <tracy.doughty@hhsys.org>, "Ron Stansell" <ron.stansell@hhsys.org>, "Wayne Byford" <wayne.byford@hhsys.org>
Sent: Monday, March 16, 2020 4:16:09 PM
Subject: albuterol MDIs

I was just in communication with Tracy Doughty and Dr. Chappell who both concur that we need to continue to build our supply of albuterol MDIs at this time. Thus, them memo that was sent out yesterday is still in effect: albuterol MDIs are only to be used on state/CDC confirmed cases of COVID-19. We will continue to pursue every avenue to increase our supply of MDIs and will let you know when/if the directive on nebs vs. MDI changes. DAVID






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved